Latest news with #WeightLoss
Medscape
15-07-2025
- Health
- Medscape
Bariatric Surgery: Who's Eligible Now?
This transcript has been edited for clarity. Bariatric surgery is a powerful tool for long-term weight loss, but it requires lifelong commitment to healthy eating, physical activity, supplements, and behavior change. When should you refer for bariatric surgery? The 2019 AACE/TOS/ASMBS guidelines recommend considering surgery for individuals with a BMI over 35 and at least one obesity-related condition — like type 2 diabetes, sleep apnea, or hypertension — or anyone with a BMI over also note that patients with a BMI from 30 to 34.9 and poorly controlled type 2 diabetes may be considered. The updated 2022 ASMBS guidelines recommend expanding eligibility to include a BMI over 30with weight-related conditions, especially for Asian populations who experience metabolic risk at lower most insurance plans still only cover surgery for a BMI over 35 with associated conditions or a BMI over 40. Because long-term weight loss is difficult due to biologic adaptations, I offer surgery as an option to all eligible patients so they can make an informed choice. Surgery may be especially appropriate for patients who prefer surgery over lifelong obesity medications — though they'll still need lifelong vitamin supplementation — those who have not achieved long-term success with lifestyle interventions and/or obesity medications, or those who have higher BMI, for whom obesity medications and lifestyle modifications may not be sufficient to lead to resolution of weight-related complications. Importantly, this does not have to be an either/or patients benefit from a combination of bariatric surgery and obesity medications to achieve meaningful, lasting weight loss and improvements in health. As always, shared decision making is key, including a clear discussion of risks, benefits, alternatives, and patient goals.
The Independent
15-07-2025
- Health
- The Independent
Hidden health benefits from weight-loss jabs revealed
Weight loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death. Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood. The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity. Roughly half of the participants were given GLP agonist drugs. These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required. The other half used other anti-diabetic medication. During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke. They were also 30 per cent less likely to die during the follow-up period. When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Fox News
11-07-2025
- Health
- Fox News
Happy Hour: Health Is Wealth, People! Featuring Jillian Michaels
Health is wealth, people! Health and Wellness Expert Jillian Michaels joins Kennedy for a tall glass of sparkling…water & organic discuss Jillian's stance on the Make America Healthy Again movement, weight loss plans, and having farm animals as Jillian shares her favorite road trip snacks. Beef jerky, anyone? Follow Kennedy on Twitter: @KennedyNation Kennedy Now Available on YouTube: Follow on TikTok: Join Kennedy for Happy Hour on Fridays! Learn more about your ad choices. Visit
The Independent
21-06-2025
- Health
- The Independent
New daily weight loss pill to rival injections
A new daily Weight Loss pill, amycretin, developed by Novo Nordisk, has shown promising results in initial studies. In trials, patients receiving weekly amycretin injections lost an average of 24.3 percent of their body weight over 36 weeks. Patients taking daily amycretin tablets achieved an average w eight loss of 13.1 percent over 12 weeks. Amycretin works by targeting GLP-1 and amylin receptors to help control blood sugar and appetite. Side effects, including nausea and vomiting, were reported as mostly mild to moderate and resolved by the end of treatment.
Yahoo
26-05-2025
- Business
- Yahoo
Diet Pills to Surpass USD 4.48 Billion By 2032 Owing to Rising Number of People with Obesity and Increasing Appetite for Non-Invasive Solutions to Weight Management
U.S. Diet Pills Market size to be valued at USD 1.08 Billion in 2032, Project at 12.90% CAGR, Rising Consumption of Prescription Drugs and Increase in the Sales of OTC in Pharmacies and E-commerce. Austin, May 26, 2025 (GLOBE NEWSWIRE) -- Diet Pills Market Size & Growth Analysis: According to SNS Insider, the global Diet Pills Market size stood at USD 1.83 billion in 2024 and is estimated to reach USD 4.48 billion by 2032, with a CAGR of 11.87% from 2025 to 2032. Rising incidence of obesity and sedentary lifestyle on a global level is driving the need for easy to use and efficient weight management methods. Increasing consumer preference for non-surgical non-invasive weight reduction procedures along with growing concern of health hazards associated with obesity is the prediction that is contributing to this a Sample Report of Diet Pills Market@ U.S. Diet Pills Market is estimated to be USD 0.44 billion in 2024 and is projected to exhibit a CAGR of 12.90% over the forecast period (2025-2032). In the U.S., the high uptake of prescription and metabolism-enhancing weight loss drugs, as well as growing OTC demand in drug stores and retail outlets, are driving growth in the U.S. market. Market Overview Diet pills are increasingly growing contoured on the background of increasing trend of obesity, diabetes, and other metabolic diseases worldwide. Worldwide estimates from recent global health data indicate that >40% of adults are overweight or obese, requiring immediate, effective weight-loss interventions. Diet pills present an attractive option to surgery and vigorous exercise. The market too has gained traction with the expansion of healthcare access and with the introduction of digital health platforms, which provides for online consultations, prescriptions and consumer awareness about weight-loss treatments. The introduction of product innovations, including appetite suppressant/metabolism booster combination products, non-stimulant options or plant-based capsules, has increased consumer use in different demographic target groups, including the young and those in whom there may be contraindications to conventional treatment. In an era of preventive health and wellness, diet pills are included in overall wellness programs. Major Players Analysis Listed in this Report are: Iovate Health Sciences Inc. Zoller Laboratories Cortislim Nanjing Chang'ao Pharmaceutical Co. Vivus Inc. Orexigen Therapeutics GlaxoSmithKline Pharmaceuticals Ltd. Gelesis Inc. Herbalife International Amway Corp. and others in the final report Diet Pills Market Report Scope Report Attributes Details Market Size in 2024 US$ 1.83 billion Market Size by 2032 US$ 4.48 billion CAGR CAGR of 11.87% From 2025 to 2032 Base Year 2023 Forecast Period 2025-2032 Historical Data 2021-2023 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: In 2024, prescription-based drugs held the largest share of the market at 62%, owing to clinical efficacy, regulatory backing, and physician trust in managing moderate to severe obesity. These drugs are often the first line of treatment for individuals with comorbidities like diabetes and hypertension. On the other hand, herbal remedies have emerged as the fastest-growing product segment. Their rise is driven by a global trend toward natural and plant-based healthcare solutions, especially among younger consumers and those wary of synthetic chemicals. By Application: Appetite-controlling pills accounted for around 48% of the market share in 2024, making them the dominant application. These pills are preferred for their ability to help regulate food intake and reduce binge-eating behaviors, which is common in sedentary urban populations. However, metabolism-boosting pills are seeing the highest growth rate. Consumers increasingly favor them for their perceived ability to burn calories efficiently, especially when combined with minimal physical activity, which aligns with the busy lifestyles of working professionals. By Distribution Channel: Retail pharmacies led the distribution channels with 53% of the market share in 2024. These outlets are accessible and trusted by consumers, offering both OTC and prescription-based diet pills. Meanwhile, hospital pharmacies are growing rapidly as healthcare providers increasingly prescribe weight loss medications in clinical settings. The credibility and availability of post-consultation guidance in hospitals make them the fastest-growing channel. Need Any Customization Research on Diet Pills Market, Enquire Now@ Diet Pills Market Segmentation By Product Type Prescription-Based Drugs Over-the-Counter Drugs Herbal Supplements By Application Metabolism Raising Pills Fat Blocking Pills Appetite Controlling Pills By Distribution Channel Hospital Pharmacy Retail Pharmacy Drug Stores Regional Analysis Asia Pacific dominated the global diet pills market in 2024, driven by rising obesity rates in densely populated countries like China and India, growing disposable income, and rapid urbanization. The regional market benefits from both traditional medicine integration and increasing acceptance of Western pharmacological treatments. North America emerged as the second-largest regional market, fueled by the high prevalence of obesity, strong pharmaceutical infrastructure, and widespread insurance coverage for prescription weight-loss medications. The U.S. market, in particular, is witnessing a surge in consumer spending on lifestyle-enhancing drugs and an increase in online pharmacy adoption. Recent Developments In March 2025, Eli Lilly reported successful mid-stage trials for orforglipron, its once-daily oral weight loss drug. The pill demonstrated significant weight reduction, potentially rivaling injectable GLP-1 therapies. In April 2025, Pfizer halted development of its oral weight-loss candidate, danuglipron, due to adverse side effects in Phase 2 trials, indicating market risks in oral anti-obesity drug development. In November 2024, Nature's Way released SlimBiotic Naturals, an herbal diet supplement containing green coffee bean extract and garcinia cambogia, entering the fast-growing plant-based pill market. In September 2024, PhenQ introduced PhenQ PM, a nighttime fat-burning formula to complement its popular daytime version, appealing to 24-hour weight management consumers. Statistical Insights and Trends Reporting Over 1 billion adults were overweight, with more than 650 million classified as obese worldwide. This demographic forms the core consumer base for diet pills. North America accounted for over 40% of global prescription diet pill sales, driven by advanced healthcare infrastructure and favorable regulatory support. The number of diet pills sold annually is projected to nearly triple from 1.2 billion units in 2020 to over 3.4 billion units by 2032, with strong demand from Asia Pacific. Consumer out-of-pocket expenditure on weight-loss supplements and prescription pills accounted for 65% of total spending in emerging economies due to limited insurance coverage. Online sales of diet pills witnessed a 45% year-on-year growth, especially in urban markets, due to increasing e-commerce penetration and discreet delivery a Single-User PDF of Diet Pills Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Obesity and Overweight Prevalence (2024), by Region 5.2 Diet Pills Consumption and Usage Trends (2024), by Region 5.3 Prescription vs. OTC Diet Pills Trends (2021–2032) 5.4 Consumer Spending on Weight Management Products, by Region (2024) 5.5 Internet & E-Commerce Sales Trends for Diet Pills (2021–2024) 5.6 Regulatory Trends and Product Approvals (Recent Years) 6. Competitive Landscape 7. Diet Pills Market by Product Type 8. Diet Pills Market by Application 9. Diet Pills Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Related Reports U.S. Anti-Obesity Drugs Market Set to Soar, Reaching $10.28 Billion by 2032 at 24.07% CAGR. Global Weight Loss Drugs Market to Skyrocket to $50.26 Billion by 2032, Growing at 43.73% CAGR. Weight Loss Supplements Market to Hit $161.03 Billion by 2030, Growing at 16.9% CAGR. Weight Loss Devices Market Forecasted to Reach $8.50 Billion by 2032, Growing at 6.60% CAGR. About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
